Investigational drug · Phase 3
ALXN2220
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Transthyretin Amyloid Cardiomyopathy, Amyloid Transthyretin Cardiomyopathy.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "ALXN2220"
First trial start
2024
Jan 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALXN2220", any sponsor or status.
Conditions studied
As listed on its trial records.
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Transthyretin Amyloid Cardiomyopathy
- Amyloid Transthyretin Cardiomyopathy
Approved drugs for the same conditions: Transthyretin amyloidosis · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "ALXN2220" as an intervention, largest first.
- Study of ALXN2220 Versus Placebo in Adults With ATTR-CMPivotal-lookingActive, not recruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT06183931 · 1,182 participants · Start Jan 11, 2024 · Primary completion Dec 6, 2027
Drug: ALXN2220; Placebo · For: Transthyretin Amyloid Cardiomyopathy
Sites: Irvine, California; La Jolla, California; Palo Alto, California · 213 sites in all
- An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid CardiomyopathyPivotal-lookingNot yet recruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT07789483 · 1,180 participants (planned) · Start Nov 23, 2027 · Primary completion Jul 11, 2030
Drug: ALXN2220 · For: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Sites: Irvine, California; La Jolla, California; Palo Alto, California · 195 sites in all
- A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CMPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07608354 · 326 participants (planned) · Start Jun 11, 2026 · Primary completion Feb 6, 2029
Drug: Eplontersen; ALXN2220 · For: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Sites: La Jolla, California; San Francisco, California; Stanford, California · 76 sites in all
- Study of Re-Treatment With ALXN2220 in Patients With ATTR-CMActive, not recruiting
Neurimmune AGIndustry
NCT07213583 · 35 participants (planned) · Start Aug 28, 2025 · Primary completion Oct 31, 2026
Drug: ALXN2220 · For: Amyloid Transthyretin Cardiomyopathy
Sites: Créteil, France; Rennes, France; Toulouse, France · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Antibody ALXN2220 (Formerly NI006) for the Treatment of Transthyretin Cardiac Amyloidosis.
Pillai AA, Frishman WH, Aronow WS · Cardiol Rev 2025
- New therapies to treat cardiac amyloidosis.
Nguyen O, Kamna D, Masri A · Curr Opin Cardiol 2025
- Advancing treatments for transthyretin amyloid cardiomyopathy: Innovations in RNA silencing, gene editing, TTR stabilization, and degradation.
Keller DM, Straburzyska-Migaj E, Lesiak M · Kardiol Pol 2025
- Prediction of Cardiac ATTR Depletion by NI006 (ALXN2220) Using Mechanistic PK/PD Modeling.
Michalon A, Renaud L, Machacek M, et al. · Clin Pharmacol Ther 2025
- Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis.
Chakrabartty A · Pharmaceuticals (Basel) 2024
- Treatment of transthyretin cardiac amyloidosis.
Bampatsias D, Wardhere A, Maurer MS · Curr Opin Cardiol 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.